Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost infusion for COVID-19 induced respiratory failure
2020-001296-33Phase 2Completed
- Sponsor
- Capital Region Blood Center
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in COVID-19 respiratory failure (CARDS) and respiratory failure comparing Ilomedin infusion with Placebo infusion (2 arms). Primary endpoint: Days alive without mechanical ventilation in the ICU at day 28. Started Apr 2020; status: completed.
02
Drugs
iloprost
03
Conditions
COVID-19 respiratory failure (CARDS)respiratory failure
Beyond the preview
Go deeper on 2020-001296-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001296-33.